Afficher la notice abrégée

dc.contributor.authorDíez Echave, Patricia 
dc.contributor.authorRuiz Malagón, Antonio Jesús 
dc.contributor.authorMolina Tijeras, José Alberto
dc.contributor.authorHidalgo García, Laura 
dc.contributor.authorVezza, Teresa
dc.contributor.authorCenis Cifuentes, Laura
dc.contributor.authorRodríguez Sojo, María Jesús 
dc.contributor.authorCenis, José Luis
dc.contributor.authorRodríguez Cabezas, María Elena 
dc.contributor.authorRodríguez Nogales, Alba 
dc.contributor.authorGálvez Peralta, Julio Juan 
dc.contributor.authorLozano-Pérez, Antonio Abel
dc.date.accessioned2021-10-18T11:22:57Z
dc.date.available2021-10-18T11:22:57Z
dc.date.issued2021-09-05
dc.identifier.citationP. Diez-Echave et al. Silk fibroin nanoparticles enhance quercetin immunomodulatory properties in DSS-induced mouse colitis. International Journal of Pharmaceutics 606 (2021) 120935. [https://doi.org/10.1016/j.ijpharm.2021.120935]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/70935
dc.descriptionThis work has been supported from the European Commission ERDF/FEDER Operational Programme `Murcia' CCI N. 2007ES161PO001 (Project No. 14-20/20), the Junta de Andalucia (CTS164), Instituto de Salud Carlos III (PI19/01058) and the Spanish MINECO (Ref. CTQ201787708-R). P.D.-E. is a postdoctoral from Junta de Andalucia (European Commission FEDER); A.J.R.-M and L.H.-G. are predoctoral fellows from University of Granada ("Programa de Doctorado: Medicina Clinica y Salud Publica"); A.A.L.-P's research contract was supported by the ERDF/FEDER Operational Programme `Murcia' CCI N 2007ES161PO001 (Project No. 14-20/20); A.R.-N. is a postdoctoral fellow of Instituto de Salud Carlos III (Miguel Servet Program); T.V. is a postdoctoral fellow from Instituto de Investigación Biosanitaria de Granada.es_ES
dc.description.abstractInflammatory bowel disease (IBD) is a chronic and idiopathic inflammatory disorder affecting the gastrointes-tinal tract. The pharmacological treatments used currently for its treatment lack efficacy, so new therapeutic strategies should be developed. In this context, flavonoids loaded in biopolymeric nanoparticles can be considered as novel promising candidates. The aim of the present study was to evaluate the intestinal anti-inflammatory effects of quercetin when is administered loaded in silk fibroin nanoparticles (QSFN) in the dextran sulphate sodium experimental model of mouse colitis, which displays some similarities to human IBD. Previously characterized quercetin-loaded silk fibroin nanoparticles (QSFN). QSFN showed a reversible aggre-gation profile induced by the acidification of the solution but did not affect the loaded quercetin. Daily administration of QSFN significantly reduced disease activity index values compared to the control colitic group. This beneficial effect was not only corroborated by the histological examination of the colonic specimens but also the improvement of the colonic expression of the different proinflammatory cytokines (Tnf-alpha, Il-1 beta, Il-6, Mcp-1, Icam-1, Nlrp3 and iNOS). Therefore, these data suggest that QSFN could be a promising alternative to current treatments as a drug delivery system for IBD treatment.es_ES
dc.description.sponsorshipEuropean Commission ERDF/FEDER Operational Programme `Murcia' CCI 2007ES161PO001- 14-20/20es_ES
dc.description.sponsorshipJunta de Andalucia CTS164es_ES
dc.description.sponsorshipInstituto de Salud Carlos III European Commission PI19/01058es_ES
dc.description.sponsorshipSpanish MINECO CTQ201787708-Res_ES
dc.description.sponsorshipERDF/FEDER Operational Programme 'Murcia' CCI 2007ES161PO001- 14-20/20es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectInflammatory bowel diseasees_ES
dc.subjectSilk fibroin nanoparticleses_ES
dc.subjectQuercetines_ES
dc.subjectAnti-inflammatoryes_ES
dc.subjectDrug loadinges_ES
dc.titleSilk fibroin nanoparticles enhance quercetin immunomodulatory properties in DSS-induced mouse colitises_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1016/j.ijpharm.2021.120935
dc.type.hasVersionVoRes_ES


Fichier(s) constituant ce document

[PDF]

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Atribución-NoComercial-SinDerivadas 3.0 España
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Atribución-NoComercial-SinDerivadas 3.0 España